Major deals boost CT biopharma sector after period of closings and layoffs
A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...
pharmaphorum17h
Merck KGaA's ATR cancer drug cleared for further trials after phase 1 trial success
Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study. Short for ataxia telangiectasia and Rad3-related ...